Default company panoramic image
Logo

Integrated Magnetic Systems Ltd

Small, uniform & low-cost all-biological magnetic nanoparticles that enable advanced applications in purification, diagnosis & therapeutics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Dundee, Scotland, GB
  • Currency GBP
  • Founded June 2009
  • Employees 11
  • Website integratedmagnetics.co.uk

Company Summary

Integrated Magnetic Systems Ltd (IMSL) sells magnetic proteins - created by genetically fusing a targeting entity with a metal binding entity - for microscale bioseparations, while further developing the platform technology for diagnostic and therapeutic opportunities in medicine. It has raised more than £500K in contracts and grants, and £1M in equity investment since becoming operational in July 2011. It has a number of live B2B collaborations.

Team

  • Default avatar
    David Evans
    Chairman

    David Evans is chairman and entrepreneurial investor in a number of companies with a demonstrable track record in both taking companies through the IPO process ( as Chairman) and delivering value to shareholders in the public phase of a company. Past Finance Director and CEO of Axis Shield and Chairman of DxS, BBI Group and Immunodiagnostics. Current Chairman of Epistem, EKF Diagnostics & Scancell. A substantial track record

  • Default avatar
    Eddie Blair
    Chief Executive Officer

    Dr Blair is also Managing Director of Integrated Medicines Ltd (IML), non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, and visiting scholar at Cambridge University. He is named inventor on many patents, including one on magnetic proteins, the technology being exploited by IMSL. Since leaving GlaxoSmithKline in 2003 (global director of clinical diagnostics) he has raised >£10M equity finance to support AIM IPOs.

  • Default avatar
    Prabs Dehal
    Chief Scientific Officer

    Dr Dehal invented the magnetic protein technology while at Axis‐Shield Diagnostics plc, where she was a principle scientist. She is a molecular immunologist specialising in the application of antibodies for immunodiagnostics and trained at the Paterson Institute and the University of Dundee in making recombinant antibodies and sub-fragments.

  • Default avatar
    Michael Martin
    Investment Adviser

    Michael Martin is an investment banker with over thirty years experience advising on Private Equity, Mergers & Acquisitions, and IPOs in Europe, USA and Asia. A founding partner of an independent corporate finance firm (Anvil Partners), he has spent the past fifteen years advising entrepreneurially led businesses on raising private equity funds and exits, and invests personally in many of these businesses.

Advisors

  • Default avatar
    George Boyle, Shepherd Wedderburn
    Lawyer
    Unconfirmed
    Default avatar
    Stephen Gibbens
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Biolink Capital Partners
    Unconfirmed
    Default avatar
    Founder
    Unconfirmed